Authorisations of human medicines

Within the framework of the authorisation procedure, Swissmedic assesses the quality, safety and effectiveness of the medicinal product in question on the basis of the comprehensive scientific documentation that is submitted.

If the criteria for authorisation are fulfilled, Swissmedic grants the marketing authorisation, specifies the method of sale (on prescription only/dispensing point) and approves the information for healthcare professionals and the patient information.

Informations

Show all

01.06.2025

Swissmedic position on conjugated pneumococcal vaccines

Swissmedic updates requirements for authorisation applications for conjugated pneumococcal vaccines

01.06.2025

Changes to the guidance document Time limits for authorisation applications

Time limits shortened for additional indications for Orbis type A and fast-track Orbis type B

01.05.2025

Risk assessment relating to nitrosamines in active substances and/or finished medicinal products

Swissmedic establishes the requirement to submit risk assessments relating to nitrosamines in active substances and/or finished medicinal products in the corresponding specification documents